Non-Small-Cell Lung Cancer Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | Merck Sharp & Dohme LLC, Suzhou Puhe Pharmaceutical Technology Co., LTD, Merus N.V., Zyme

Non-Small-Cell Lung Cancer Pipeline constitutes 100+ key companies continuously working towards developing 120+ Non-Small-Cell Lung Cancer treatment therapies, analyzes DelveInsight.

Non-Small-Cell Lung Cancer Overview:

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, originating in lung tissues and typically growing more slowly than small cell lung cancer (SCLC). However, it often spreads to other parts of the body before diagnosis, making early detection and treatment crucial. Lung cancer affects approximately 230,000 people annually in the United States, with around 135,000 deaths per year. It remains the leading cause of cancer-related deaths in men and the second most common in women, though rates are declining due to anti-smoking campaigns and reduced tobacco use.
Types of NSCLC
NSCLC includes several subtypes, classified based on the 2015 World Health Organization (WHO) system using immunohistochemistry and light microscopy:
Adenocarcinoma - The most common form, accounting for half of all lung cancer cases.
Squamous cell carcinoma (SCC) - Previously the most diagnosed, it usually begins in the tracheobronchial tree but is now also found in the lung periphery.
Large cell carcinoma - A poorly differentiated form diagnosed by exclusion, as it lacks defining features under immunohistochemistry or electron microscopy.
Causes and Risk Factors
NSCLC risk factors fall into avoidable and unavoidable categories.
Avoidable risks include tobacco use, alcohol consumption, and exposure to secondhand smoke, asbestos, radon, arsenic, chromium, nickel, ionizing radiation, and polycyclic aromatic hydrocarbons.
Unavoidable risks include genetic predisposition and environmental exposures beyond an individual's control.
Due to its high mortality rate and late-stage detection, early screening and targeted treatment approaches are essential for improving survival outcomes.
Request for a detailed insights report on Non-Small-Cell Lung Cancer pipeline insights @ https://www.delveinsight.com/report-store/non-small-cell-lung-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

"Non-Small-Cell Lung Cancer Pipeline Insight 2024" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Non-Small-Cell Lung Cancer Therapeutics Market.

Key Takeaways from the Non-Small-Cell Lung Cancer Pipeline Report

DelveInsight's Non-Small-Cell Lung Cancer pipeline report depicts a robust space with 100+ active players working to develop 120+ pipeline therapies for Non-Small-Cell Lung Cancer treatment.
In December 2024, the FDA awarded breakthrough therapy designation to sacituzumab tirumotecan (MK-2870/SKB264/) for the treatment of patients with advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC).
In December 2024, Xcovery Holdings, Inc., a pharmaceutical company specializing in oncology, announced that the U.S. Food and Drug Administration (FDA) had approved ensartinib (Ensacove) for the treatment of patients with ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). This approval marks a significant milestone in expanding first-line treatment options for individuals with ALK-positive NSCLC.
In September 2024, AbbVie announced the submission of a Biologics License Application (BLA) to the US FDA for the accelerated approval of elotuzumab vedotin (Teliso-V) in adult patients with previously treated, locally advanced, or metastatic epidermal growth factor receptor (EGFR) wild-type nonsquamous NSCLC with c-Met protein overexpression.
In August 2024, the FDA granted Fast Track designation to Deltacel (KB-GDT-01) in combination with low-dose radiation therapy as a potential treatment for patients with metastatic NSCLC whose disease has progressed after at least two prior standard-of-care treatments, including immune checkpoint inhibitors, platinum-based chemotherapy, and targeted therapies.
Key Non-Small-Cell Lung Cancer companies such as Merck Sharp & Dohme LLC, Suzhou Puhe Pharmaceutical Technology Co., LTD, Merus N.V., Zymeworks BC Inc., Cytos Biotechnology, Exelixis, ProfoundBio US Co., Beijing Pearl Biotechnology Limited Liability Company, Pfizer, OncoResponse, Inc., Next Point Therapeutics, Inc., Light Chain Bioscience - Novimmune SA, Medolution Ltd., Immunitas Therapeutics, Shanghai Henlius Biotech, and others are evaluating new drugs for Non-Small-Cell Lung Cancer to improve the treatment landscape.
Promising Non-Small-Cell Lung Cancer pipeline therapies in various stages of development include V940, QL1706, Zenocutuzumab (MCLA-128), ZW49, and others.

Non-Small-Cell Lung Cancer Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Non-Small-Cell Lung Cancer Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Non-Small-Cell Lung Cancer treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Non-Small-Cell Lung Cancer market.

Download our free sample page report on Non-Small-Cell Lung Cancer pipeline insights @ https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Non-Small-Cell Lung Cancer Emerging Drugs

V940: Merck Sharp & Dohme LLC
QL1706: Qilu Pharmaceutical Co., Ltd.
Zenocutuzumab (MCLA-128): Merus N.V.
ZW49: Zymeworks BC Inc.

Non-Small-Cell Lung Cancer Companies

There are over 100 prominent companies actively working on developing therapies for Non-Small Cell Lung Cancer (NSCLC). Among them, Merck Sharp & Dohme LLC has its NSCLC drug candidates in the most advanced stage of development, specifically Phase III.

DelveInsight's report covers around 120+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Non-Small-Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Non-Small-Cell Lung Cancer Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Non-Small-Cell Lung Cancer Therapies and Key Companies: Non-Small-Cell Lung Cancer Clinical Trials and advancements @ https://www.delveinsight.com/report-store/non-small-cell-lung-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Non-Small-Cell Lung Cancer Pipeline Therapeutic Assessment
• Non-Small-Cell Lung Cancer Assessment by Product Type
• Non-Small-Cell Lung Cancer By Stage
• Non-Small-Cell Lung Cancer Assessment by Route of Administration
• Non-Small-Cell Lung Cancer Assessment by Molecule Type

Download Non-Small-Cell Lung Cancer Sample report to know in detail about the Non-Small-Cell Lung Cancer treatment market @ Non-Small-Cell Lung Cancer Therapeutic Assessment @ https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Content

1. Report Introduction
2. Executive Summary
3. Non-Small-Cell Lung Cancer Current Treatment Patterns
4. Non-Small-Cell Lung Cancer - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Non-Small-Cell Lung Cancer Late-Stage Products (Phase-III)
7. Non-Small-Cell Lung Cancer Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Non-Small-Cell Lung Cancer Discontinued Products
13. Non-Small-Cell Lung Cancer Product Profiles
14. Non-Small-Cell Lung Cancer Key Companies
15. Non-Small-Cell Lung Cancer Key Products
16. Dormant and Discontinued Products
17. Non-Small-Cell Lung Cancer Unmet Needs
18. Non-Small-Cell Lung Cancer Future Perspectives
19. Non-Small-Cell Lung Cancer Analyst Review
20. Appendix
21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Non-Small-Cell Lung Cancer Pipeline Reports Offerings: https://www.delveinsight.com/report-store/non-small-cell-lung-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.